PFE - Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment | Benzinga
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a treatment forpatients suffering from specific type of endometrial cancer. Its pharma peer, BioNTech SE (NASDAQ: BNTX) wasn’t as lucky as also on Monday, the FDA put its experimental cancer drug study on partial clinical hold.
Combining Immunotherapy And Chemotherapy Is Emerging As A New Standard In Cancer Treatment
On Monday, the Anglo-Swedish pharmaceutical company revealed its late-stage trial showed that the combination of Imfinzi and chemotherapy drugs carboplatin and paclitaxel, followed by Imfinzi by itself, reduced the risk of disease progression or death by 58% in adult suffering from primary, advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), compared to chemotherapy alone. Endometrial cancer is the fourth most prevalent cancer ...